Chlamydia Infections - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chlamydia Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Chlamydia Infections - Pipeline Review, H1 2016', provides an overview of the Chlamydia Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chlamydia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections
- The report reviews pipeline therapeutics for Chlamydia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chlamydia Infections therapeutics and enlists all their major and minor projects
- The report assesses Chlamydia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chlamydia Infections

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chlamydia Infections Overview 7
Therapeutics Development 8
Pipeline Products for Chlamydia Infections - Overview 8
Pipeline Products for Chlamydia Infections - Comparative Analysis 9
Chlamydia Infections - Therapeutics under Development by Companies 10
Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes 11
Chlamydia Infections - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Chlamydia Infections - Products under Development by Companies 14
Chlamydia Infections - Products under Investigation by Universities/Institutes 15
Chlamydia Infections - Companies Involved in Therapeutics Development 16
Abera Bioscience AB 16
Adamis Pharmaceuticals Corporation 17
CEL-SCI Corporation 18
Genocea Biosciences, Inc. 19
Merck & Co., Inc. 20
NanoBio Corporation 21
Prokarium Limited 22
QureTech Bio AB 23
Selecta Biosciences, Inc. 24
SIGA Technologies, Inc. 25
Chlamydia Infections - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Ab-03 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
acALY-18 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
C-31G - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CEL-1000 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Chlamydia trachomatis vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Chlamydia trachomatis vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Chlamydia vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
chlamydia vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Chlamydia vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Chlamydia vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Chlamydia vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Chlamydia vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GEN-001 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules for Chlamydophila Infections - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
solithromycin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ST-669 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Chlamydia Infections - Recent Pipeline Updates 58
Chlamydia Infections - Dormant Projects 69
Chlamydia Infections - Product Development Milestones 70
Featured News & Press Releases 70
Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice 70
Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology 70
Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia 71
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 72
Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria 72
Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center 73
Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for Chlamydia Infections, H1 2016 8
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2016 16
Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 17
Chlamydia Infections - Pipeline by CEL-SCI Corporation, H1 2016 18
Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H1 2016 19
Chlamydia Infections - Pipeline by Merck & Co., Inc., H1 2016 20
Chlamydia Infections - Pipeline by NanoBio Corporation, H1 2016 21
Chlamydia Infections - Pipeline by Prokarium Limited, H1 2016 22
Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2016 23
Chlamydia Infections - Pipeline by Selecta Biosciences, Inc., H1 2016 24
Chlamydia Infections - Pipeline by SIGA Technologies, Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Chlamydia Infections Therapeutics - Recent Pipeline Updates, H1 2016 58
Chlamydia Infections - Dormant Projects, H1 2016 69